Navigation Links
New treatment option for patients with chronic hepatitis C

A new combination therapy of daily consensus interferon (CIFN) and ribavirin is effective for some people with chronic hepatitis C (HCV) who do not respond to standard therapy. The treatment works particularly well in interferon-sensitive patients who have lower fibrosis scores, according to a new study in the June issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD).

Nearly half of all HCV patients do not respond to the standard therapy of pegylated interferon and ribavirin. They remain at risk for developing life-threatening liver disease. So far, other alternative therapies have not been particularly successful in these nonresponders.

One new treatment with the potential to help patients with persistent HCV involves high doses of daily consensus interferon (CIFN) combined with ribavirin. Researchers, led by Bruce Bacon of St. Louis University, conducted a multicenter trial to examine the efficacy, tolerability and safety of this approach.

The researchers studied 487 patients whose HCV had not responded to initial treatment with standard therapy. Many had characteristics that generally bode poorly for treatment response. Nearly all had HCV genotype 1; 80 percent had not responded strongly to their previous treatment; 68 percent had high baseline levels of the virus in their blood; 60 percent had advanced liver disease; and about 20 percent were African-American. These factors have all been shown to reduce rates of sustained viral response after treatment.

The patients were divided into three groups. Two would receive the new therapy at different doses, and the third would receive no therapy. After 24 weeks, the control group was stratified into one of the treatment arms.

Ultimately, 245 of the patients received 9 mcg of CIFN daily along with ribavirin, and 242 others took 15 mcg of CIFN daily along with ribavirin. After 24 weeks, patients with detectable HCV RNA were considered non-responders and stopped the therapy. Responders continued taking their therapy up through week 48, and were then followed-up through week 72. If HCV RNA was detected between weeks 48 and 72, the patient was classified as a relapser.

Nearly 7 percent of the patients taking 9 mcg of CIBN, and 10.7 percent of those taking 15 mcg, achieved a sustained viral response. The rates were even higher among patients who had responded better to the standard therapy and among those who had lower baseline fibrosis scores.

"The best response rate, 31.6 percent, was observed in noncirrhotic patients who had a partial virologic response with a greater than 2-log10 decline in HCV RNA during their previous course of peg-IFN treatment," the authors report.

While adverse events were common, most patients continued their treatment in spite of them. Common side effects were neutropenia, fatigue, leucopenia, depression, nausea, muscle pain, lymphopenia and anemia.

"The present study demonstrated that some patients with chronic hepatitis C who have failed to respond to treatment with peg-IFN and RBV can be successfully retreated with daily CIFN and RBV," the authors conclude. "The greatest SVR rate during retreatment in the present study was observed in F0-F3 patients who had a partial virologic response during their prior course of treatment."


Contact: Sean Wagner

Related medicine news :

1. New treatment effective in counteracting cocaine-induced symptoms
2. New treatment boosts muscle function in myasthenia gravis
3. Broad-based group of physicians calls for improvement in stroke treatment
4. Cranberry Could Juice Up Ovarian Cancer Treatment
5. Non-medicinal treatment touted for pre-schoolers with ADHD
6. Nonmedicinal treatment touted for preschoolers with ADHD
7. U of M study: Early treatment can reverse heart damage
8. Biologic treatment for rheumatoid arthritis and the risk of cancer
9. New Treatment Explored for Cluster Headaches
10. Thailand: Partners Open Free AIDS Treatment Clinic in Renowned AIDS Temple in Lop Buri
11. 4-Star Gen. Barry Mccaffrey, Former U.S. Drug Czar, to Keynote Recovery Happens! Rally for Treatment: Wed., Sept. 5, 11 Am, State Capitol West Steps, Sacramento
Post Your Comments:
(Date:11/30/2015)... ... , ... While powdered supplements and drinks can reduce food preparation time, locating ... Va., has found an easy to keep track of the scoop. , He developed ... in a canister or other container handy and readily accessible. As such, it prevents ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... just publishing magazines and websites specializing in independent living, assisted living and all ... paramount, and Alzheimer’s awareness and research remains a top priority. ...
(Date:11/30/2015)... Morton Grove, IL (PRWEB) , ... November 30, 2015 , ... ... milestone for an emerging pharmaceutical company. Because it is so important to this key ... titled “Success Factors in your IND Filing” on December 4th at 11am EST. , ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... of critical importance to the medical schools of the future. To reach an ... suite at the 2015 ChangeMedEd conference in Chicago, organized by the American Medical ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... are pleased to announce their strategic partnership at the Radiological Society of ... Service, Inc., and Winscribe, global providers of cutting-edge dictation and speech-enabled documentation ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... , Nov. 30, 2015  Precision Image ... services, is pleased to announce a dramatic expansion ... imaging services. Building on its ISO-9001:2008 certification for ... implemented comprehensive Core Lab protocols and procedures. This ... of research activities.  Their Core Lab services include ...
(Date:11/30/2015)... Sectra (STO: SECT B) ... into a multi-year agreement to provide Breast Imaging PACS ... Breast Care to increase collaboration with sub-specialists around the ... --> Sectra (STO: SECT B) ... into a multi-year agreement to provide Breast Imaging PACS ...
(Date:11/29/2015)... Nov. 29, 2015 CIVCO Medical Solutions ... at the Radiological Society of North ... Chicago November 29 – December 4, ... to offer customers unrivaled versatility, enhanced user experience ... --> ...
Breaking Medicine Technology: